This Week at FDA: Midterms may complicate Overton confirmation, influence user fee reauthorization, and more

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, we’re looking at some of the ways the midterm election results could impact FDA over the next two years, starting with the confirmation prospects for President Trump’s pick for FDA commissioner and how Democrats may use their newfound oversight powers.